OncoMatch/Clinical Trials/NCT06366490
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Is NCT06366490 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Innocell Autologous Cellular Immunotherapy for ovarian cancer.
Treatment: Innocell Autologous Cellular Immunotherapy — Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
has received at least 1 line of platinum-based systemic therapy
Must have received: PARP inhibitor
PARP inhibitors for women with germline BRCA mutation and in homologous recombination repair deficiency based on prior molecular testing
Must have received: VEGF inhibitor (bevacizumab)
bevacizumab as appropriate
Cannot have received: systemic therapy
treatment with an approved systemic therapy within 3 weeks of planned vaccine initiation
Cannot have received: investigational agent
received any other investigational agents within 4 weeks of planned vaccine initiation
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify